Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink.

Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L.

BMJ. 2013 Apr 12;346:f1936. doi: 10.1136/bmj.f1936.

2.

Risk of colorectal cancer after initiation of orlistat: matched cohort study.

Hong JL, Meier CR, Sandler RS, Jick SS, Stürmer T.

BMJ. 2013 Aug 27;347:f5039. doi: 10.1136/bmj.f5039.

3.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
4.

Safety profile of orlistat: results of a prescription-event monitoring study.

Acharya NV, Wilton LV, Shakir SA.

Int J Obes (Lond). 2006 Nov;30(11):1645-52. Epub 2006 Mar 21.

PMID:
16552401
5.

Orlistat: hepatitis and oxalate nephropathy.

[No authors listed]

Prescrire Int. 2012 Mar;21(125):71. No abstract available.

PMID:
22428191
6.

Orlistat: should we worry about liver inflammation?

Wilding J.

BMJ. 2013 Apr 30;346:f2777. doi: 10.1136/bmj.f2777. No abstract available.

PMID:
23633008
7.
8.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.

O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G.

Health Technol Assess. 2001;5(18):1-81. Review.

9.

Risk of acute liver injury in patients with diabetes.

Huerta C, Zhao SZ, García Rodríguez LA.

Pharmacotherapy. 2002 Sep;22(9):1091-6.

PMID:
12222543
10.

Ascertainment of acute liver injury in two European primary care databases.

Ruigómez A, Brauer R, Rodríguez LA, Huerta C, Requena G, Gil M, de Abajo F, Downey G, Bate A, Tepie MF, de Groot M, Schlienger R, Reynolds R, Klungel O.

Eur J Clin Pharmacol. 2014 Oct;70(10):1227-35. doi: 10.1007/s00228-014-1721-y. Epub 2014 Jul 29.

PMID:
25066450
11.

Orlistat-induced fulminant hepatic failure.

Sall D, Wang J, Rashkin M, Welch M, Droege C, Schauer D.

Clin Obes. 2014 Dec;4(6):342-7. doi: 10.1111/cob.12075. Epub 2014 Sep 29.

PMID:
25826164
12.

An integrated analysis of liver safety data from orlistat clinical trials.

Morris M, Lane P, Lee K, Parks D.

Obes Facts. 2012;5(4):485-94. doi: 10.1159/000341589. Epub 2012 Jul 23.

13.

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.

Diabetes Obes Metab. 2005 Nov;7(6):699-708.

PMID:
16219013
14.

The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.

Perrio MJ, Wilton LV, Shakir SA.

Obesity (Silver Spring). 2007 Nov;15(11):2712-22.

15.

The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom.

Hayes JF, Bhaskaran K, Batterham R, Smeeth L, Douglas I.

Int J Obes (Lond). 2015 Sep;39(9):1359-64. doi: 10.1038/ijo.2015.86. Epub 2015 May 14.

16.

Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial.

Cassiman D, Roelants M, Vandenplas G, Van der Merwe SW, Mertens A, Libbrecht L, Verslype C, Fevery J, Aerts R, Pirenne J, Muls E, Nevens F.

Transpl Int. 2006 Dec;19(12):1000-5.

17.

Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial.

Bloch KV, Salles GF, Muxfeldt ES, Da Rocha Nogueira A.

J Hypertens. 2003 Nov;21(11):2159-65.

PMID:
14597860
18.

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.

Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.

Diabetes Nutr Metab. 2004 Aug;17(4):222-9.

PMID:
15575343
19.

A systematic review of the clinical effectiveness of orlistat used for the management of obesity.

O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G.

Obes Rev. 2004 Feb;5(1):51-68. Review.

PMID:
14969507
20.

Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.

Czernichow S, Knol MJ, Fezeu L, Grobbee DE.

Eur J Prev Cardiol. 2012 Jun;19(3):484-9. doi: 10.1177/1741826711406058. Epub 2011 Apr 4.

PMID:
21464100
Items per page

Supplemental Content

Write to the Help Desk